Genenta Science SPA ADR GNTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.59
- Day Range
- $1.48–1.59
- 52-Week Range
- $0.55–10.00
- Bid/Ask
- $1.45 / $1.50
- Shares Outstanding
- 48.22M
- Market Cap
- $35.39M
- Volume/Avg
- 3,606 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 9
- Website
- https://www.genenta.com
Valuation
|
Metric
|
GNTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.40 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GNTA
|
|---|---|
Quick Ratio | 13.90 |
Current Ratio | 14.16 |
Interest Coverage | — |
Quick Ratio
GNTA
Profitability
|
Metric
|
GNTA
|
|---|---|
Return on Assets (Normalized) | −19.53% |
Return on Equity (Normalized) | −28.71% |
Return on Invested Capital (Normalized) | −24.61% |
Return on Assets
GNTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|rK<@^<! | LOCK|ZmFMW | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|M?DDr! | LOCK|sC?@M | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<CPVZ$ | LOCK|Mk | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|T&!$<<B | LOCK|>YNN> | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<$M@&^ | LOCK|Bd | $36B | |||
| Moderna Inc
MRNA
| LOCK|y@TXd^s | LOCK|>< | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!@<^dLC | LOCK|t#>BJ | $25B | |||
| Incyte Corp
INCY
| LOCK|!%&bz?$ | LOCK|VXz | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|P@hTt? | LOCK|q? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|BHN<nx | LOCK|W$b | $17B |
United States